证券代码：300246 证券简称：宝莱特 公告编号：2025-061 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、证券代码：300246，证券简称：宝莱特 2、债券代码：123065，债券简称：宝莱转债 3、转股价格：24.02 元/股 4、转股期限：2021 年 3 月 11 日至 2026 年 9 月 3 日 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）规定：在本次发行的可转 换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格的90%时，公司董事会有权提出转股价格向下修正 方案并提交公司股东会表决。 2025年9月10日至2025年9月23日，公司股票已有10个交易日的收盘价格低于 当期转股价格（24.02元/股）的90%，预计可能触发"宝莱转债"转股价格向下修 正条件。若触发转股价格向下修正条款 ...

Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. participated in the "2025 Guangdong Listed Companies Investor Online Reception Day" on September 19, 2025, to engage with investors and discuss company performance and future strategies [1]. Group 1: Financial Performance - In the first half of 2025, the subsidiary Suzhou Junkang reported a net profit of 6.70 million yuan, with an operating loss of 4.37 million yuan, and has been consolidated into the company's financial statements [1]. - For the first half of 2025, the net profit attributable to shareholders of the listed company was 1.31 million yuan, an increase of 152.22% year-on-year. The total assets at the end of the reporting period were 2.41 billion yuan, a decrease of 3.66% from the beginning of the year [1]. - The company's equity attributable to the parent company was 1.22 billion yuan, an increase of 0.25% from the beginning of the year. Cost reduction measures led to a decrease in expenses, but revenue and product profits declined due to price reductions in blood dialysis consumables and other factors [1]. Group 2: Business Strategy - The company focuses on two main business segments: "Life Information and Support" and "Renal Medical," aiming to become a leader in critical care and nephrology [1]. - In the Life Information and Support segment, the company emphasizes clinical needs, leveraging technological advancements to innovate and create differentiated solutions [1]. - In the Renal Medical segment, the company is developing differentiated consumables for hemodialysis and exploring technologies in peritoneal dialysis and CRRT, with plans to launch a CRRT machine integrated with overall solutions [1]. Group 3: Future Plans - The company is actively seeking related targets in the industry chain and will communicate investor suggestions to the board [1]. - The dialysis device production line project at Suzhou Junkang is expected to be operational by June 30, 2026, with an annual production capacity of 12 million dialysis devices [1]. - Due to strategic adjustments, the German subsidiary is currently undergoing asset disposal [1].

Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 52,343.60 million yuan, a year-on-year decrease of 2.43% [6] - The net profit attributable to shareholders was 131.34 million yuan, an increase of 152.22% year-on-year [6] - Total assets at the end of the reporting period were 240,748.13 million yuan, a decrease of 3.66% from the beginning of the period [6] - Equity attributable to shareholders increased by 0.25% to 122,170.35 million yuan [6] Group 2: Subsidiary Performance - The subsidiary Suzhou Jun Kang reported a net profit of 670.09 million yuan in the first half of 2025, but an operating loss of -436.95 million yuan [4] - The company plans to enhance product development and market expansion to achieve profitability for Suzhou Jun Kang [4] Group 3: Strategic Focus - The company is committed to its two main business segments: "Life Information and Support" and "Renal Medical" [2] - It aims to innovate and develop intelligent medical devices that address clinical pain points, transitioning from "functional integration" to "intelligent decision-making" [2] - The company is actively seeking related targets in the industry chain for potential acquisitions [3] Group 4: Future Plans - In 2025, the company will focus on high-end, intelligent, and IoT-enabled new products, while enhancing the penetration of high-margin products [8] - The company is leveraging opportunities from medical infrastructure expansion, hospital upgrades, and accelerated domestic substitution [8] - Plans include improving operational efficiency through lean management and cost reduction initiatives [8] Group 5: Project Developments - The Suzhou Jun Kang dialysis production line project is expected to produce 12 million dialysis devices annually, with completion targeted for June 30, 2026 [7] - The German subsidiary is undergoing asset management due to strategic adjustments [7]

证券日报网讯宝莱特9月22日在互动平台回答投资者提问时表示，截至2025年6月30日公司股东人数为 18，406户，最新的股东人数请关注公司定期报告。 （文章来源：证券日报） ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-060 债券代码：123065 债券简称：宝莱转债 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。届时公司部分董事、高级管理人员将在线就经营状况、公司治理、 发展战略等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 广东宝莱特医用科技股份有限公司 董事会 2025 年 9 月 17 日 广东宝莱特医用科技股份有限公司 关于参加 2025 年广东辖区投资者网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东宝莱特医用科技股份有限公司（以 下简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提 质 价值领航——2025 年广东辖区上市公司投资者网上集体接待日"活动，现将 相关事项公告如下： ...

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [1][2]. - The company’s monitoring equipment is utilized in thousands of medical institutions across China [1]. Product Categories - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems [2]. - In the renal medical field, Baolait has a complete industrial chain with eight consumable bases and a channel platform, providing products for blood dialysis and peritoneal dialysis [2]. Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 523.44 million, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to CNY 1.31 million [3]. - Total assets at the end of the reporting period were CNY 2.41 billion, a decrease of 3.66% from the beginning of the year [3]. R&D and Innovation - The company is focusing on clinical needs and technological innovation, aiming to integrate smart technology into product development to address core clinical pain points [4]. - Baolait's high-end monitoring products feature unique parameters and advanced technologies, enhancing their competitiveness in the market [5]. Market Demand and Opportunities - The number of blood dialysis patients in 2024 is projected to be 1.027 million, maintaining a compound annual growth rate of approximately 12% over the past decade [6]. - The company is actively expanding into the home dialysis market, particularly automated peritoneal dialysis, which has shown a growth rate of over 10% in recent years [7]. International Expansion - Baolait's blood dialysis products have begun to penetrate overseas markets, with a reported revenue growth of 121.29% in the first half of 2025 [8]. - The company is monitoring new policies related to blood dialysis and has developed products that meet the latest regulatory requirements [8]. New Product Launches - Recent product launches include peritoneal dialysis machines and smart monitoring devices, enhancing the company's product line in life information and support [8]. - The BioView C100 visual laryngoscope and S200 smart enteral nutrition pump were showcased at CMEF, featuring advanced imaging and safety features [8].

Group 1 - The core point of the article is that Baolait has announced the approval of the proposal to reappoint the accounting firm during its third extraordinary general meeting of shareholders in 2025 [2] Group 2 - The announcement was made on the evening of September 2 [2] - The proposal was part of the agenda for the extraordinary general meeting [2]

广东精诚粤衡律师事务所 法律意见书 广东精诚粤衡律师事务所 关于广东宝莱特医用科技股份有限公司 2025 年第三次临时股东会的 法律意见书 致：广东宝莱特医用科技股份有限公司（下称"贵公司"） 广东精诚粤衡律师事务所（以下简称"本所"）接受贵公司的委托，就贵 公司 2025 年第三次临时股东会（以下简称"本次股东会"）出具法律意见。为 此，本所律师查阅了有关贵公司本次股东会的资料，并指派律师出席了贵公司 于 2025 年 9 月 2 日召开的本次股东会。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》《广 东宝莱特医用科技股份有限公司章程》等法律法规的规定，就贵公司本次股东 会的召集、召开程序、出席会议的人员资格、股东会议案和股东会的表决程序 和表决结果等事项发表法律意见，不对本次股东会所审议议案的内容以及在议 案中所涉及的事实和数据的真实性和准确性等问题发表意见。 本所律师是依据本法律意见书出具日以前已经发生的事实的了解和对法律 的理解发表法律意见。 本所律师按照律师业公认的业务标准道德规范和勤勉尽责精神，对贵公司 提供的有关文件和资料进行了审查和验证，现出具法律意见如下： 广东精诚粤衡律师事 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-059 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1. 本次会议无否决或变更提案的情况； 股东出席的总体情况： 通过现场和网络投票的股东 161 人，代表股份 78,316,484 股，占公司有表决 权股份总数的 29.9369％。 其中：通过现场投票的股东 4 人，代表股份 77,319,334 股，占公司有表决权 1 证券代码：300246 证券简称：宝莱特 公告编号：2025-059 2. 本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 广东宝莱特医用科技股份有限公司（以下简称"公司"）2025 年第三次临时股 东会会议于 2025 年 9 月 2 日（星期二）14:30 在珠海市高新区永和路 9 号公司会 议室以现场会议及网络投票的方式召开。 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 2 日 9:15-9:25， ...

Group 1 - The company will pay interest on its convertible bonds, "宝莱转债," on September 4, 2025, for the period from September 4, 2024, to September 3, 2025, at a coupon rate of 2.5% [2][4] - Each holder of 10 bonds (with a face value of 1,000 RMB each) will receive 25.00 RMB in interest (including tax) [4][5] - The interest payment will be made through China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, to the registered bondholders as of the close of trading on September 3, 2025 [5][6] Group 2 - The interest income tax for individual bondholders is set at a rate of 20%, which will be withheld by the payment agents when distributing the interest [4][6] - Foreign institutional investors are exempt from corporate income tax and value-added tax on the interest income from these bonds until December 31, 2025 [6]